Medical device developers are replacing human volunteers with AI-generated virtual patients to test new implants and tools before they ever reach a real person. This matters because traditional clinical trials for medical devices are slow, expensive, and often fail to include enough people from different ages, ethnicities, or health backgrounds. A device that works well in a narrow test group can cause unexpected complications once it reaches a broader population. EQUIVALENCE uses generative AI to create thousands of synthetic patients that mimic real-world diversity, then runs entire clinical trials in a computer—a process called in-silico testing. If the project succeeds, regulators could approve devices based partly on virtual trials, cutting development time and cost dramatically. Smaller companies could afford the kind of rigorous testing now reserved for large corporations. The approach also reduces the need for animal testing and early-stage human trials. Most importantly, it allows developers to test devices against rare but dangerous scenarios—such as an unusual anatomy or a specific combination of health conditions—that would be impractical to study in a conventional trial.
View original technical description
Project EQUIVALENCE: Revolutionising Medical Device Testing with Virtual Populations Medical device testing is at a critical juncture. Traditional clinical trials, while valuable, are often limited in scope, time-consuming, and expensive. They may not adequately represent diverse populations, potentially leading to unforeseen complications when devices are widely deployed. EQUIVALENCE aims to address these challenges by refining, translating, and demonstrating the efficacy of a unique approach to creating high-quality, high-volume synthetic virtual populations for medical device testing. At the heart of EQUIVALENCE is a groundbreaking in-silico trials capability that leverages advanced generative AI modelling. This innovative technology creates synthetic virtual patients that closely mimic the diversity and complexity of real-world populations. Our aim is to demonstrate that these in-silico trials can replicate key safety and efficacy outcomes of conventional clinical trials, but at a fraction of the cost and time. The project focuses on three main objectives: 1. Refinement: We will enhance our existing virtual population generation technology, improving its accuracy, diversity, and scalability. This will involve integrating new data sources and advanced AI algorithms to create more comprehensive and representative virtual patient cohorts. 1. Translation: We will develop protocols and workflows to translate traditional clinical trial designs into in silico formats. This includes creating virtual analogues of medical interventions and defining virtual endpoints that correspond to real-world clinical outcomes. 1. Demonstration: We will conduct a series of virtual trials, paralleling completed real-world clinical trials for specific medical devices. By comparing the outcomes, we aim to validate the equivalence of our in-silico approach to traditional methods. The potential impact of EQUIVALENCE is substantial. Successful demonstration of this technology could accelerate medical device development, reduce costs, and most importantly, improve patient safety by enabling more comprehensive testing across diverse virtual populations. It could allow for the exploration of rare but critical scenarios that are difficult to encounter in traditional trials. Moreover, this approach aligns with ethical imperatives to reduce animal testing and minimise risk to human participants in early-stage trials. It also offers the potential to democratise medical device development, allowing smaller companies to conduct comprehensive testing that was previously only feasible for large corporations. EQUIVALENCE represents a significant step towards a future where medical devices are developed faster, tested more thoroughly, and designed with greater consideration for diverse patient populations. Our goal is to set a new standard in medical device testing, ultimately benefiting patients worldwide through safer, more effective medical technologies.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know